07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

PT001: Phase II started

Pearl began a double-blind, placebo-controlled, crossover, U.S. Phase II trial to compare 4 doses of twice-daily PT001 administered via a metered dose inhaler for 7 days vs. open-label Atrovent ipratropium HFA inhalation aerosol in about...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

Boehringer Ingelheim sales and marketing update

Boehringer's Boehringer Ingelheim Pharmaceuticals Inc. unit (Ridgefield, Conn.) launched Atrovent HFA ipratropium inhaled bronchodilator in the U.S. for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). Boehringer Ingelheim GmbH, Ingelheim, Germany...
08:00 , Nov 22, 2004 |  BC Week In Review  |  Clinical News

Atrovent HFA regulatory update

FDA approved Atrovent HFA inhalation aerosol, a reformulation of Atrovent (CFC), for bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Boehringer Ingelheim Corp., Ridgefield, Conn.   Product: Atrovent HFA   Business:...